Breast Cancer clinical trial intelligence

"Effect of Supervised Resistance Training on Arm Volume and Quality of Life amONG Women at High Risk for Breast Cancer-related Lymphedema: a Study Protocol for a Randomized Controlled Trial (STRONG-B)"

"Effect of Supervised Resistance Training on Arm Volume and Quality of Life amONG Women at High Risk for Breast Cancer-related Lymphedema: a Study Protocol for a Randomized Controlled Trial (STRONG-B)" is a NA clinical asset sponsored by Pontificia Universidad Catolica de Chile in Breast Cancer, Physical Activity, Lymphedema of Upper Arm. SEO and diligence focus: Resistance Training, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Breast Cancer

A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer

The Phase III trial of Atezolizumab in combination with chemotherapy for operable Stage II-III Triple Negative Breast Cancer (TNBC) was terminated after an interim analysis indicated that the primary endpoint of invasive disease-free survival (iDFS) crossed a pre-specified futility boundary. This outcome suggests limited commercial viability for this combination therapy in the TNBC market, which is highly competitive with existing therapies. The termination may impact Hoffmann-La Roche's strategic positioning in the immuno-oncology space, particularly against other PD-1/PD-L1 inhibitors and chemotherapy regimens. Stakeholders should assess the implications for future development and potential reallocation of resources towards more promising assets.

Matched by conditions: Triple Negative Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

The QuantifyHER study, sponsored by the Abramson Cancer Center at Penn Medicine, aims to evaluate a quantitative HER2 assay for its ability to predict treatment response in patients with HER2-low metastatic breast cancer receiving T-DXd (Enhertu). This study targets a niche yet significant segment of the breast cancer market, particularly focusing on patients with HER2 IHC 1+ expression. The findings could enhance the precision of HER2-targeted therapies, potentially leading to improved patient outcomes and positioning the sponsor favorably in the competitive landscape of breast cancer therapeutics. The study's collaboration with Danaher Inc. may also indicate a strategic partnership for diagnostic development, which could further strengthen market positioning.

Matched by conditions: HER2-positive Metastatic Breast Cancer

Phase I Trial of Escalating Doses of Anti-PD1 Monoclonal Antibody (CT-011) in Combination With p53 Vaccine in Adults With Advanced Solid Tumors

The trial investigates the combination of CT-011, an anti-PD-1 monoclonal antibody, with a p53 vaccine in patients with advanced solid tumors that have not responded to standard therapies. This combination aims to enhance immune recognition and destruction of cancer cells with p53 mutations. Given the increasing focus on immuno-oncology, successful outcomes could position this therapy favorably in a competitive market, particularly against existing PD-1/PD-L1 inhibitors. However, the trial's withdrawal status raises concerns regarding the feasibility and potential market entry of this combination therapy. Further diligence is required to assess the implications of this withdrawal on ongoing and future development efforts.

Matched by conditions: Breast Cancer

Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer

The AJMUC1 clinical trial, sponsored by Sun Yat-Sen Memorial Hospital, explores a novel immunotherapy approach for advanced MUC1-positive breast cancer, a population with limited effective treatment options. The trial's completion in November 2022 positions it for potential market entry, contingent on favorable safety and efficacy results. The competitive landscape includes established CAR-T therapies and emerging immunotherapies targeting similar malignancies. The success of AJMUC1 could provide a unique therapeutic avenue, particularly for patients who have exhausted standard treatment options, thereby addressing a significant unmet medical need. Diligence should focus on the trial's safety profile, potential market size, and the regulatory pathway for CAR-T therapies in China and globally.

Matched by conditions: Advanced Breast Cancer

A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

Bellicum Pharmaceuticals is advancing BPX-603, a HER2-targeted dual-switch CAR-T cell therapy, aimed at treating advanced HER2-positive solid tumors. The market for HER2-targeted therapies is significant, particularly in breast and gastric cancers, where existing therapies may have limited efficacy in heavily pre-treated populations. The suspension of the trial due to dose-limiting toxicity in a related study raises concerns regarding safety and may impact investor confidence and future funding. However, if successful, BPX-603 could provide a novel treatment option in a competitive landscape dominated by established therapies such as trastuzumab and newer agents. The potential for a differentiated safety profile through the dual-switch mechanism may enhance its market positioning.

Matched by conditions: HER2-positive Breast Cancer

Phase I Clinical Study of Chimeric Antigen Receptor T Cells (C-13-60) in the Treatment of Carcinoembryonic Antigen (CEA) Positive Advanced Malignant Solid Tumors

Chongqing Precision Biotech Co., Ltd is advancing its C-13-60 CAR-T cell therapy targeting CEA-positive advanced malignant solid tumors through a Phase I clinical trial. The trial aims to establish safety, tolerability, and pharmacokinetics while preliminarily assessing efficacy. The targeted patient population includes those with advanced colorectal, esophageal, gastric, pancreatic, non-small cell lung, breast, and cholangiocarcinoma who have exhausted standard treatment options. The success of this trial could position C-13-60 as a novel therapeutic option in a competitive landscape dominated by existing CAR-T therapies and immune checkpoint inhibitors. Given the high unmet need in these indications, particularly in late-stage cancers, there is significant market potential if the therapy demonstrates favorable outcomes. The trial's recruitment status is currently active, with an estimated completion date in 2027, indicating a long-term investment horizon for stakeholders.

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

This Phase II trial, sponsored by the National Cancer Institute, investigates the efficacy of neoadjuvant chemotherapy regimens in hormone receptor-poor/HER2-negative breast cancer, a segment with significant unmet medical need. The inclusion of carboplatin and bevacizumab may enhance pathologic complete response rates, potentially positioning these combinations as competitive options in the neoadjuvant setting. The results could influence treatment guidelines and market dynamics, particularly for therapies targeting this specific breast cancer subtype. Companies involved in breast cancer therapeutics should monitor outcomes closely for potential shifts in standard of care and consider implications for their own product pipelines.

Matched by conditions: Stage IIA Breast Cancer AJCC v6 and v7

Phase 1 Study: Induction of Systemic Immune Responses in Metastatic Breast Cancer Patients by Vaccination With a CD80-modified, Devitalized HLA-*A0201+ Breast Cancer Cell Line (KS24.22)

The Phase 1 trial conducted by University Hospital Tuebingen aims to evaluate the safety and feasibility of a novel immunotherapy approach using a genetically modified allogeneic breast cancer cell line. Given the increasing focus on personalized and targeted therapies in oncology, this study positions itself within a competitive landscape that includes other immunotherapeutic strategies for metastatic breast cancer. The successful demonstration of safety and immunogenicity could pave the way for further development and potential partnerships or licensing opportunities, particularly as the market for breast cancer therapies continues to expand. However, the trial's completion in 2010 suggests that further development may hinge on subsequent studies and data analysis to establish a clear therapeutic advantage over existing treatments.

Pre-habilitation Program for Women Indicated to Breast Cancer Surgical Treatment.

The pre-habilitation program for women undergoing surgical treatment for breast cancer addresses a significant unmet need in oncology care, particularly in Brazil, where breast cancer is the most prevalent cancer among women. With an estimated 625,000 new cancer cases annually, this trial could position the Instituto Nacional de Cancer as a leader in innovative cancer care strategies. The findings may support the integration of pre-habilitation programs into standard oncology practice, potentially influencing reimbursement policies and expanding market opportunities for related health and wellness products. The competitive landscape includes other supportive care interventions, but this trial's focus on physical exercise and nutritional guidance may differentiate it in the market. Stakeholders should monitor the trial's outcomes closely for implications on treatment protocols and potential partnerships with health organizations.

A Window of Opportunity Study of Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Hormone Receptor-positive Breast Cancer.

This Phase II trial, sponsored by St Vincent's Hospital, investigates the efficacy of pre-operative endocrine therapy with and without Prometrium (progesterone) in postmenopausal women with early-stage HR+ HER2- breast cancer. The study aims to explore potential additive effects of progesterone on standard endocrine therapies (letrozole and tamoxifen). Given the significant market for breast cancer therapies, particularly in hormone receptor-positive subtypes, successful outcomes could enhance treatment options and market share for involved therapies. The trial's findings may also influence future treatment guidelines and positioning of Prometrium in combination therapies, potentially impacting competitive dynamics in the oncology space.

Matched by conditions: Early-stage Breast Cancer

Use of Dibenzyl Trisulphide as a Chemotherapeutic Agent in Stage Four Cancer of the Breast, Prostate, Cervix and Colon

The clinical trial, sponsored by The University of The West Indies, aims to evaluate the efficacy of Dibenzyl Trisulphide in patients with stage IV cancers, including breast, prostate, cervical, and colon cancers. Given the increasing demand for alternative cancer therapies, particularly in late-stage disease settings, this trial could position Dibenzyl Trisulphide as a novel treatment option. The market for cancer therapeutics is highly competitive, with numerous established players; however, if successful, this asset could fill a niche for patients seeking complementary or alternative treatments. Diligence should focus on the regulatory landscape, potential market access challenges, and the need for robust clinical data to support claims of efficacy and safety.

Matched by conditions: Stage IV Breast Cancer

An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts.

Boehringer Ingelheim's trial evaluates the combination of Xentuzumab and Abemaciclib in advanced solid tumors, particularly in breast cancer and NSCLC. The focus on hormone receptor-positive breast cancer aligns with a significant market opportunity, given the increasing prevalence of breast cancer and the demand for effective therapies. The competitive landscape includes established CDK4/6 inhibitors like Palbociclib and Ribociclib, necessitating a robust differentiation strategy based on safety and efficacy profiles. Successful outcomes could enhance Boehringer Ingelheim's oncology portfolio and provide leverage in negotiations with payers and healthcare providers.

An Open-label Study to Evaluate the Safety and Effect on Disease Progression and Overall Survival of Avastin Plus Taxane-based Chemotherapy in Patients With Locally Recurrent or Metastatic Breast Cancer

The study evaluates the combination of Avastin and taxane-based chemotherapy in patients with locally recurrent or metastatic HER-2 negative breast cancer. Given the substantial patient population (500+), the results could reinforce Avastin's positioning in the competitive landscape against other therapies targeting similar indications. The market for breast cancer treatments remains robust, with ongoing demand for effective first-line therapies. Competitive analysis suggests that while Avastin faces competition from other anti-VEGF agents and novel therapies, its established use and safety profile may provide a strategic advantage. Diligence should focus on the long-term efficacy and safety data, as well as potential regulatory hurdles in various markets.

Matched by conditions: Breast Cancer